Search results
BioNTech SE (NASDAQ:BNTX) Position Reduced by Vontobel Holding Ltd.
ETF DAILY NEWS· 18 hours agoVontobel Holding Ltd. trimmed its stake in shares of BioNTech SE (NASDAQ:BNTX – Free Report) by 33.7% during the fourth quarter, according to its most recent filing with the ...
BioNTech (NASDAQ:BNTX) Sees Strong Trading Volume
ETF DAILY NEWS· 19 hours agoBioNTech SE (NASDAQ:BNTX – Get Free Report) shares saw unusually-high trading volume on Tuesday . Approximately 308,533 shares were traded during mid-day trading, a decline ...
AACR: BioNTech's Genentech-partnered cancer vax still providing immune response 3 years later
FierceBiotech· 2 weeks agoThree years after receiving BioNTech’s cancer vaccine in a phase 1 trial, patients with a...
Mirae Asset Global Investments Co. Ltd. Sells 44,290 Shares of BioNTech SE (NASDAQ:BNTX)
ETF DAILY NEWS· 2 days agoMirae Asset Global Investments Co. Ltd. reduced its position in BioNTech SE (NASDAQ:BNTX – Free Report) by 54.6% in the fourth quarter, according to its most recent disclosure ...
BMO keeps Outperform on BioNTech shares amid promising vaccines development
Investing.com· 1 week agoOn Tuesday, BMO Capital Markets sustained its Outperform rating for BioNTech (NASDAQ: BNTX ) shares...
Is Pfizer Stock A Sell As Shares Hit A 9-Year Low Amid The Search For Its Next Big Break?
Investor's Business Daily· 10 hours agoPfizer stock is trading at a nine-year low as the drugmaker looks for its next big break after...
Who can get a Covid booster this spring and how can you book?
BBC via Yahoo News· 5 days agoSpring vaccinations will be available until 30 June. Which vaccine will people get? Vaccines from...
Only One Harm From mRNA COVID Vaccines, Report Determines
MedPage Today· 3 days agoAt the same time, the National Academies of Sciences, Engineering, and Medicine (NASEM) committee...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 2 weeks agoThree-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran (BNT122, RO7198457) continue to show polyspecific T cell responses up to three years and delayed tumor
COVID-19 booster immunity lasts much longer than primary series alone, study shows
Medical Xpress· 6 hours agoThe study used Canadian vaccine data collected from individuals living in long-term care, as well as frontline health-care workers working in long-term...
